share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  08/16 16:09

Moomoo AI 已提取核心信息

On August 16, 2024, NeuroSense Therapeutics Ltd., a foreign private issuer, announced the entry into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC. Under this agreement, NeuroSense may offer and sell ordinary shares with a total value of up to $2,524,437. The sales are to be conducted through an 'at the market offering' as defined by Rule 415 under the Securities Act of 1933, with the possibility of sales on The Nasdaq Capital Market or other trading markets. The offering will be made pursuant to a shelf registration statement and prospectus filed with the SEC in January 2023. NeuroSense is not obligated to sell any shares and the agreement may be terminated by either party or by mutual agreement. The Sales Agent will...Show More
On August 16, 2024, NeuroSense Therapeutics Ltd., a foreign private issuer, announced the entry into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC. Under this agreement, NeuroSense may offer and sell ordinary shares with a total value of up to $2,524,437. The sales are to be conducted through an 'at the market offering' as defined by Rule 415 under the Securities Act of 1933, with the possibility of sales on The Nasdaq Capital Market or other trading markets. The offering will be made pursuant to a shelf registration statement and prospectus filed with the SEC in January 2023. NeuroSense is not obligated to sell any shares and the agreement may be terminated by either party or by mutual agreement. The Sales Agent will receive a 3% commission on gross proceeds and will be indemnified by NeuroSense, which will also reimburse certain expenses. The agreement includes customary representations, warranties, and conditions. This report, along with the full text of the Sales Agreement and the legal opinion of Goldfarb Gross Seligman & Co., is incorporated by reference into the company's existing registration statements.
2024年8月16日，外国私人发行人NeuroSense Therapeutics Ltd.宣布与JonesTrading Institutional Services LLC签订了《按需资本销售协议》。在该协议下，神经感应可以提供并出售总价值高达2,524,437美元的普通股票。销售将通过根据1933年证券法规定的415号规则定义的'按市场交易'进行，并有可能在纳斯达克资本市场或其他交易市场进行销售。这项优惠将根据在2023年1月提交给SEC的注册声明和招股说明来进行。NeuroSense没有义务出售任何股份，该协议可以被任何一方或共同协议终止。销售代理将获得毛收益的3%佣金，并由NeuroSense进行赔偿，NeuroSense还将报销某些费用。协议包括习惯性的声明、保证和条件。该报告以及销售协议的全文以及Goldfarb Gross Seligman & Co.的法律意见，均已通过参考形式并入该公司现有的注册声明中。
2024年8月16日，外国私人发行人NeuroSense Therapeutics Ltd.宣布与JonesTrading Institutional Services LLC签订了《按需资本销售协议》。在该协议下，神经感应可以提供并出售总价值高达2,524,437美元的普通股票。销售将通过根据1933年证券法规定的415号规则定义的'按市场交易'进行，并有可能在纳斯达克资本市场或其他交易市场进行销售。这项优惠将根据在2023年1月提交给SEC的注册声明和招股说明来进行。NeuroSense没有义务出售任何股份，该协议可以被任何一方或共同协议终止。销售代理将获得毛收益的3%佣金，并由NeuroSense进行赔偿，NeuroSense还将报销某些费用。协议包括习惯性的声明、保证和条件。该报告以及销售协议的全文以及Goldfarb Gross Seligman & Co.的法律意见，均已通过参考形式并入该公司现有的注册声明中。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间